Observational studyBMC gastroenterology2025
Comparative analysis of tenofovir alafenamide and entecavir on renal function and serum lipids in liver transplant recipients: a controlled retrospective cohort study.
Observational study in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiviral treatments can impact serum lipids as well as kidney function. We conducted a retrospective observational study with a 48-month follow-up period, involving liver transplant recipients receiving either entecavir or tenofovir alafenamide, to assess the effects of these antiviral medications on serum lipids and renal function.
methodsThe study was conducted with 47 patients. Research data were retrospectively collected. Serum creatinine and lipid levels were measured at least once per year for each patient. The Friedman test was applied to compare estimated glomerular filtration rate (eGFR) and serum lipids.
results. During the 48-month observation period, a mean decrease in eGFR of 10 mL/min/1.73 m² was observed in the tenofovir alafenamide treatment group (p < 0.001), while a decrease of 8 mL/min/1.73 m² occurred in the entecavir group (p < 0.001). However, there was no statistically significant difference in the eGFR decrease between the two groups (p = 0.990). Although entecavir showed more favorable effects on total cholesterol compared to tenofovir alafenamide at the 12th and 24th months (p = 0.025 and p = 0.023, respectively), neither treatment demonstrated a lipid-lowering effect by the end of the 48-month observation period.
conclusionWe found no significant difference in renal safety between tenofovir alafenamide and entecavir; however, the relatively small sample size and retrospective design limit the power to detect subtle differences. Entecavir was associated with a more favorable lipid profile compared to tenofovir alafenamide during the first two years of treatment, with modest reductions in total cholesterol observed at 12 and 24 months. Overall, both entecavir and tenofovir alafenamide have similar impacts on serum lipids and renal function, making them safe and effective treatment options for liver transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.